Monopar Therapeutics (MNPR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 17, 2025, at company headquarters in Wilmette, IL.
Shareholders can vote online, by mail, or in person, with voting closing June 16, 2025.
Proxy materials and annual report for 2024 are available online or by request.
Voting matters and shareholder proposals
Election of six directors: Christopher M. Starr, Chandler D. Robinson, Raymond W. Anderson, Arthur J. Klausner, Kim R. Tsuchimoto, and Lavina Talukdar.
Advisory vote to approve executive compensation.
Advisory vote on the frequency of future say-on-pay votes, with board recommending every year.
Ratification of BPM LLP as independent auditor for fiscal year ending December 31, 2025.
Proxies may vote on other matters arising at the meeting at their discretion.
Board of directors and corporate governance
Board recommends all director nominees for election.
Latest events from Monopar Therapeutics
- ALXN1840 shows long-term efficacy in Wilson disease; MNPR-101 advances in oncology trials.MNPR
Investor presentation20 Mar 2026 - Biopharma seeks to raise up to $300M for rare disease and oncology pipeline via flexible shelf offering.MNPR
Registration Filing16 Dec 2025 - Registering 705,015 shares for resale by a pharma partner after a licensing and equity deal.MNPR
Registration Filing16 Dec 2025 - Biotech registers 882,761 shares for resale after $21M private placement to fund drug development.MNPR
Registration Filing16 Dec 2025 - Key votes include director elections, auditor ratification, a reverse split, and stock plan amendment.MNPR
Proxy Filing2 Dec 2025 - Key votes include director elections, auditor ratification, reverse split, and stock plan amendment.MNPR
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, executive pay, auditor, and board governance.MNPR
Proxy Filing2 Dec 2025 - $143.7M cash post-raise supports late-stage ALXN1840 and radiopharma pipeline through 2027.MNPR
Q3 202513 Nov 2025 - Strong cash reserves support clinical progress as net loss rises with increased R&D and G&A.MNPR
Q2 202512 Aug 2025